Bone marrow transplantation for thalassemia in Hong Kong: the early experience.
The first experience of bone marrow transplantation (BMT) for thalassemia in Hong Kong is reported. Of the three children transplanted using a matched allogeneic donor, two have been surviving disease free 291 and 256 days post-BMT respectively. The other child rejected the graft and remained transfusion dependent. Mild graft versus host disease occurred in one of the children which subsided on cyclosporin A alone. The regimen-related toxicities were mild and easily manageable. Thus the result is encouraging and the procedure is now accepted as an option of treatment for good risk patients in Hong Kong.
Department of Pediatrics, Queen Mary Hospital, Hong Kong.
A C
AC
Lee
Y L
YL
Lau
C F
CF
Chan
E
E
Chiu
R
R
Liang
T K
TK
Chan
C Y
CY
Yeung
D016026:Bone Marrow Transplantation; D002648:Child; D002675:Child, Preschool; D005260:Female; D006085:Graft Survival / Q000187:drug effects; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use; D006723:Hong Kong; D006801:Humans; D008297:Male; D011994:Recombinant Proteins / Q000627:therapeutic use; D016896:Treatment Outcome; D017086:beta-Thalassemia / Q000601:surgery*
D011994:Recombinant Proteins; D016178:Granulocyte-Macrophage Colony-Stimulating Factor